CTLA4 and neoplasm: Curran et al. combined α-CTLA-4 and α-PD-L1 mAb treatment of an implantable model of B16 melanoma and observed more than a 2-fold increase in tumor rejection compared to α-CTLA-4 mAb alone treated groups [8].